
LCI765 is an orally active and селективный PPARδ агонист, with an EC50 of 0.07 nM. LCI765 can be used for the research of diseases related to energy homeostasis such as metabolic syndrome.
LCI765 is an orally active and selective PPARδ agonist, with an EC50 of 0.07 nM. LCI765 can be used for the research of diseases related to energy homeostasis such as metabolic syndrome.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.